Research
Print page Print page
Switch language
  1. The Capital Region of Denmark
  2. Publications
  3. CHEK2 (∗) 1100delC Mutation an...
  4. Citationformats
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hale, V, Weischer, M & Park, JY 2014, 'CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer', Prostate Cancer, vol. 2014, pp. 294575. https://doi.org/10.1155/2014/294575

APA

Hale, V., Weischer, M., & Park, J. Y. (2014). CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer, 2014, 294575. https://doi.org/10.1155/2014/294575

CBE

Hale V, Weischer M, Park JY. 2014. CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer. 2014:294575. https://doi.org/10.1155/2014/294575

MLA

Hale, Victoria, Maren Weischer and Jong Y Park. "CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer". Prostate Cancer. 2014, 2014. 294575. https://doi.org/10.1155/2014/294575

Vancouver

Hale V, Weischer M, Park JY. CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer. 2014;2014:294575. https://doi.org/10.1155/2014/294575

Author

Hale, Victoria ; Weischer, Maren ; Park, Jong Y. / CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. In: Prostate Cancer. 2014 ; Vol. 2014. pp. 294575.

Bibtex

@article{f810a328be3e495cbc8859a77787041e,
title = "CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer",
abstract = "Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer. CHEK2 plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current knowledge of the role of a genetic variant, 1100delC, of CHEK2 on prostate cancer risk and discuss the implication for potential translation of this knowledge into clinical practice. Currently, twelve articles that discussed CHEK2 (∗)1100delC and its association with prostate cancer were identified. Of the twelve prostate cancer studies, five studies had independent data to draw conclusive evidence from. The pooled results of OR and 95% CI were 1.98 (1.23-3.18) for unselected cases and 3.39 (1.78-6.47) for familial cases, indicating that CHEK2 (∗)1100delC mutation is associated with increased risk of prostate cancer. Screening for CHEK2(∗)1100delC should be considered in men with a familial history of prostate cancer.",
author = "Victoria Hale and Maren Weischer and Park, {Jong Y}",
year = "2014",
doi = "10.1155/2014/294575",
language = "English",
volume = "2014",
pages = "294575",
journal = "Prostate Cancer",
issn = "2090-3111",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer

AU - Hale, Victoria

AU - Weischer, Maren

AU - Park, Jong Y

PY - 2014

Y1 - 2014

N2 - Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer. CHEK2 plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current knowledge of the role of a genetic variant, 1100delC, of CHEK2 on prostate cancer risk and discuss the implication for potential translation of this knowledge into clinical practice. Currently, twelve articles that discussed CHEK2 (∗)1100delC and its association with prostate cancer were identified. Of the twelve prostate cancer studies, five studies had independent data to draw conclusive evidence from. The pooled results of OR and 95% CI were 1.98 (1.23-3.18) for unselected cases and 3.39 (1.78-6.47) for familial cases, indicating that CHEK2 (∗)1100delC mutation is associated with increased risk of prostate cancer. Screening for CHEK2(∗)1100delC should be considered in men with a familial history of prostate cancer.

AB - Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer. CHEK2 plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current knowledge of the role of a genetic variant, 1100delC, of CHEK2 on prostate cancer risk and discuss the implication for potential translation of this knowledge into clinical practice. Currently, twelve articles that discussed CHEK2 (∗)1100delC and its association with prostate cancer were identified. Of the twelve prostate cancer studies, five studies had independent data to draw conclusive evidence from. The pooled results of OR and 95% CI were 1.98 (1.23-3.18) for unselected cases and 3.39 (1.78-6.47) for familial cases, indicating that CHEK2 (∗)1100delC mutation is associated with increased risk of prostate cancer. Screening for CHEK2(∗)1100delC should be considered in men with a familial history of prostate cancer.

U2 - 10.1155/2014/294575

DO - 10.1155/2014/294575

M3 - Journal article

C2 - 25431674

VL - 2014

SP - 294575

JO - Prostate Cancer

JF - Prostate Cancer

SN - 2090-3111

ER -

ID: 44848071